ADC Technology Market Revenue to Cross USD 4 billion by 2035 | Roots Analysis

Published: August 2023


According to a recently published report by Roots Analysis, the rising demand for more efficient and homogenous antibody drug conjugates is driving the ADC technology market growth

ADC Technology Industry Overview

The global ADC technology market size was estimated at USD 1.18 billion in 2023 and is expected to reach over USD 4.37 billion by 2035, growing at a CAGR of 11.5% in the forecast period 2023-2035.

Antibody drug conjugates are a complex and versatile form of anti-cancer therapy, which have been proven to be more effective and less toxic to patients.  Such interventions are designed to identify specific antigens that are expressed on the surface of cancer (target) cells so that the effects of the cytotoxin / drug are focused on the elimination of only the cancerous cells.  Owing to the target specificity component, the approach reduces the chances of damaging normal cells.  Over the years, this class of therapeutics has undergone several improvements, most of which were focused on how the highly potent cytotoxic component could be attached to the segment that confers specificity (the antibody). The physical attachment of the aforementioned components is facilitated in a process that is commonly referred to as conjugation, or bioconjugation.

Browse 140+ figures and 200+ market data tables spread across 400+ pages and detailed Table of Content on “ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) by Generation of ADC Technology, Type of Conjugation, Type of Linker and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/adc-technologies-market/287.html

Market Drivers

One of the key drivers of the ADC technology market size is the increasing number of investments and collaborations between leading players. In order to fulfil the growing demand for antibody drug conjugates, significant investments have been made in the ADC technology market. In fact, various large and mid-sized players have invested heavily, to gain access to the novel and innovative ADC technologies, for the production of efficient and homogeneous ADCs. One such example of player includes Synaffix. Over the years, Synaffix has entered into various licensing agreements, through which the company is anticipated to receive a sum of USD 5.35 billion in terms of upfront and milestone payments.

Market Restraints

Although, antibody drug conjugates is a very promising drug class for targeting oncological disorders. However, ADC development and manufacturing is challenging and cost intensive process. Owing to the complex structure of antibody drug conjugates, the market growth of this industry has not reached it complete potential. Moreover, the number of side effects associated with the antibody drug conjugates asks for very selective types of conjugation and linker technologies, thereby limiting the growth of ADC technology market.

Growth Factors

Despite the challenges, several growth factors continue to drive the ADC technology market forward. One notable factor is the generation of site-specific conjugation technologies. These technologies have the potential to develop more stable and precise antibody drug conjugates. Moreover, the resulting ADCs offer lesser off-target effects and increased concentration towards the tumor sites. In fact, owing to the ever evolving domain of ADC technology, several ADCs have been introduced to the development pipeline that are more stable and are homogenous in nature.

ADC Technology Market Segments

Based on the generation of technology, the market is segmented into Third-Generation, Second-Generation and Next-Generation.

  • The third-generation segment led the ADC technology market, capturing the largest revenue share of close to 85.0% in 2023.
  • The next-generation segment is anticipated to show the highest market growth potential during the forecast period of over 18% annually.

Based on the type of conjugation, the market is segmented into Chemical, Chemoenzymatic and Enzymatic.

  • The chemical conjugation segment led the ADC technology market, capturing the largest revenue share of over 45.0% in 2023.
  • The chemoenzymatic conjugation segment is anticipated to show the highest market growth potential during the forecast period of over 12.5% annually.

Based on the type of linker, the market is segmented into cleavable and non-cleavable.

  • The cleavable linker segment led the ADC technology market, capturing the largest revenue share of around 85% in 2023.
  • In fact, the cleavable linker segment is anticipated to show the highest growth potential by growing at a CAGR of over 12% during the forecast period.

Based on the payment model adopted, the market is segmented into Upfront Payments and Milestone Payments.

  • The milestone payment segment led the ADC technology market, capturing the largest revenue share of close to 60.0% in 2023.
  • In fact, the milestone payment segment is anticipated to show the highest growth potential by growing at a CAGR of close to 13% during the forecast period.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.

  • North America dominated the ADC technology market and accounted for the largest revenue share of close to 39.0% in 2023.
  • In Asia-Pacific and rest of the world, the ADC technology market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The ADC Technology market report also includes detailed profiles of key players (listed below) that offer ADC technologies products:

  • Alteogen
  • Ambrx
  • Antikor
  • Catalent Biologics
  • Heidelberg Pharma
  • Iksuda Therapeutics
  • LegoChem Biosciences
  • Mersana Therapeutics
  • NBE-Therapeutics
  • Seattle Genetics
  • Sutro Biopharma

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/adc-technologies-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry